Anlotinib Hydrochloride in Intra-Abdominal Desmoplastic Small Round Cell Tumor: Case Evidence and Research Context

Study Background and Research Question

Intra-abdominal desmoplastic small round cell tumor (IADSRCT) is a rare, highly aggressive sarcoma characterized by the EWS-WT1 gene fusion and a marked predilection for young males. Prognosis remains dismal, with five-year overall survival rates between 15%–30%. Conventional management typically involves multimodal strategies—surgical resection, aggressive chemotherapy, and occasionally radiotherapy—but no standard therapeutic guideline exists. The scarcity of effective options for metastatic IADSRCT has driven interest in molecularly targeted therapies, especially those capable of disrupting tumor angiogenesis and microenvironmental support.

Multi-target tyrosine kinase inhibitors (TKIs), notably those interfering with VEGFR, PDGFR, and FGFR signaling axes, have demonstrated clinical impact in various solid tumors. However, their application in IADSRCT has not been previously documented. The reference case study addresses this knowledge gap by reporting the first successful use of anlotinib hydrochloride in a patient with metastatic IADSRCT, with a focus on clinical outcomes and mechanistic plausibility.

Key Innovation from the Reference Study

The central innovation of the reference case report lies in the demonstration of clinical benefit from anlotinib hydrochloride—a next-generation, orally bioavailable multi-target TKI—in a setting where previous lines of therapy had limited efficacy. Unlike earlier studies that focused on common carcinomas, this report provides the first evidence for anlotinib’s activity in IADSRCT, contributing a new therapeutic possibility for this orphan disease.

Anlotinib targets several receptor tyrosine kinases implicated in tumor angiogenesis and cell proliferation, including VEGFR1/2/3, FGFR1–4, PDGFRα/β, c-Kit, and MET. This broad inhibition profile is mechanistically aligned with the highly vascular phenotype and microenvironmental complexity of IADSRCT. The case report supports the translational hypothesis that multi-target anti-angiogenic agents may provide clinical benefit in rare soft tissue sarcomas previously considered refractory to such approaches.

Methods and Experimental Design Insights

The study presents a single-patient case report with a well-documented clinical course. A 38-year-old male with histopathologically confirmed IADSRCT, initially managed with complete surgical resection and six cycles of adjuvant chemotherapy, exhibited lymph node metastases on follow-up imaging. Given the lack of standardized salvage therapies, the patient was prescribed anlotinib hydrochloride as per an off-label, compassionate-use protocol.

Anlotinib was administered orally, and disease response was monitored by serial computed tomography (CT). Key endpoints included radiographic changes in lymph node size and clinical tolerability. Laboratory assessments and adverse event monitoring were performed according to standard clinical practice.

Protocol Parameters

• Anlotinib dosing: Initiated after failure of surgery and chemotherapy; clinical dosing should follow established safety protocols for multi-target TKIs.
• Treatment monitoring: Serial CT imaging to assess lymph node and metastatic lesion response every 2–4 cycles.
• Toxicity surveillance: Regular assessment of triglycerides, fatigue, and other adverse events; dose modifications as needed for grade ≥2 toxicity.
• Baseline evaluation: Comprehensive immunohistochemistry and molecular diagnostics to confirm IADSRCT diagnosis and exclude alternative small round cell neoplasms.

Core Findings and Why They Matter

Following four cycles of anlotinib, the patient achieved a marked reduction in the size of metastatic lymph nodes, with imaging confirming partial remission. Maintenance therapy with anlotinib was well tolerated, and the patient remained in good clinical condition at the time of reporting. Side effects were limited to hypertriglyceridemia and mild fatigue, both manageable with supportive measures.

This clinical outcome is significant for several reasons. First, it demonstrates that anlotinib can induce regression of metastatic IADSRCT lesions even after standard therapies have failed, supporting its mechanistic rationale as an inhibitor of angiogenic and proliferative signaling. Second, the observed safety profile is consistent with prior TKI experiences in other cancers, suggesting translational feasibility. Finally, the case offers a concrete precedent for further evaluation of multi-target TKIs in rare, angiogenesis-dependent sarcomas, potentially informing future trial designs or compassionate-use protocols.

Mechanistically, these clinical observations are underpinned by anlotinib’s robust inhibition of VEGFR, PDGFR, and FGFR signaling, pathways known to mediate tumor vasculature and stromal interactions. Previous preclinical studies show that anlotinib potently suppresses endothelial cell migration and capillary tube formation—key events in tumor neovascularization—at nanomolar concentrations (see internal review). This aligns with the clinical response observed in the case report, supporting the hypothesis that angiogenesis inhibition is a valid strategy in IADSRCT.

Comparison with Existing Internal Articles

Recent internal literature further corroborates the reference study’s findings. For instance, one review discusses anlotinib hydrochloride’s multitargeted inhibition of VEGFR2, PDGFRβ, and FGFR1, highlighting its superior efficacy over earlier TKIs in both in vitro and translational models. These mechanistic insights are echoed in additional preclinical benchmarking, which emphasizes enhanced selectivity and reproducibility in dissecting angiogenic signaling networks.

Such internal resources reinforce the translational context of the reference case. The convergence of preclinical, mechanistic, and now clinical evidence strengthens the rationale for deploying anlotinib hydrochloride in research and potentially, investigational therapy for rare sarcomas like IADSRCT. Notably, these articles provide detailed protocols on endothelial cell migration inhibition and capillary tube formation assays—relevant for those seeking to model anlotinib’s mode of action in vitro.

Limitations and Transferability

As a single-patient case report, the evidence must be interpreted with caution. The absence of a control group, potential confounders such as prior therapies, and limited follow-up duration restrict the generalizability of the findings. Additionally, the unique molecular features of IADSRCT (e.g., EWS-WT1 fusion) may limit transferability to other sarcoma subtypes or solid tumors without similar angiogenic drivers.

The safety and efficacy profile observed here should be validated in larger, prospective studies. Further research is needed to elucidate optimal dosing, long-term outcomes, and potential resistance mechanisms.

Why this cross-domain matters, maturity, and limitations

The cross-domain application of multitargeted tyrosine kinase inhibition in a rare sarcoma—traditionally managed with cytotoxic regimens—demonstrates the translational maturity of anti-angiogenic strategies. However, the evidence remains preliminary, and broader adoption awaits confirmatory data from larger clinical cohorts or basket trials encompassing similar rare, angiogenesis-driven tumors.

Research Support Resources

For researchers aiming to recapitulate or extend these findings in preclinical or translational workflows, Anlotinib hydrochloride (SKU C8688) is available as a research-use-only reagent. Its well-characterized inhibition of VEGFR2, PDGFRβ, and FGFR1, combined with a favorable safety profile in functional assays, supports its use in endothelial migration, capillary tube formation, and ERK pathway inhibition studies. Detailed pharmacokinetic and safety data can be found in the product dossier. Researchers are encouraged to consult both the reference paper and cited internal articles for further protocol guidance and mechanistic context.